Oral Prolonged‐Release Oxycodone/Naloxone for Managing Pain and Opioid‐Induced Constipation: A Review of the Evidence
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background: Opioids provide effective relief from moderate‐to‐severe pain and should be prescribed as part of a multifaceted approach to pain management when other treatments have failed. Fixed‐dose oxycodone/naloxone prolonged‐release tablets (OXN PR) were designed to address the opioid class effect of opioid‐induced constipation (OIC) by combining the analgesic efficacy of oxycodone with the opioid receptor antagonist, naloxone, which has negligible systemic availability when administered orally. This formulation has abuse‐deterrent properties, since systemic exposure to naloxone by parenteral administration would antagonize the euphoric effects of oxycodone. Methods: A literature search was conducted to assess the evidence base for OXN PR to treat moderate‐to‐severe pain and its impact on bowel function, based on published clinical trials and observational studies. Results: Extensive data demonstrate that OXN PR provides effective analgesia and clinically relevant improvements in bowel function in patients with OIC and moderate‐to‐severe cancer‐related pain and noncancer pain types such as low back pain, neuropathic pain, and musculoskeletal pain. OXN PR has also been found to improve bowel function in patients with OIC refractory to multiple types of laxatives, and improve Parkinson's disease–related pain. No unanticipated safety concerns have been reported in elderly patients. Conclusions: Evidence from clinical trials and observational studies confirms that for selected patients OXN PR significantly improves moderate‐to‐severe chronic pain and provides relief from OIC. Treatment should be tailored to individual patients to establish the lowest effective dose. An absence of analgesic ceiling effect was seen across the clinically relevant dose range investigated (≤ 160/80 mg/day).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpää, M., Hansson, P., Jensen, T. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70251-0 · Cited by 3,980
Chou, R., Gordon, D. B., de Leon-Casasola, O. A., Rosenberg, J. M., Bickler, S., Brennan, T., Carter, T., Cassidy, C. L., Chittenden, E. H., Degenhardt, E., et al. (2016) · The Journal of Pain · doi:10.1016/j.jpain.2015.12.008 · Cited by 3,171 · cited 1×
“and short-acting oral opioids are generally preferred over long-acting oral opioids for the immediate postoperative period, due in part to dose titration requirements.(90) Our literature search identified 8 studies investigating short-term administration of OXN PR to”
BackgroundChou, R., Qaseem, A., Snow, V., Casey, D., Cross, J. T., Shekelle, P., Owens, D. K., & for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians and the American College of Physicians/American Pain Society Low Back Pain Guidelines Panel* (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-7-200710020-00006 · Cited by 2,718
Chapter 4 European guidelines for the management of chronic nonspecific low back pain
Airaksinen, O., Brox, J. I., Cedraschi, C., Hildebrandt, J., Klaber-Moffett, J., Kovacs, F., Mannion, A. F., Reis, S., Staal, J. B., Ursin, H., et al. (2006) · European Spine Journal · doi:10.1007/s00586-006-1072-1 · Cited by 2,594
Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain
Chou, R., Fanciullo, G. J., Fine, P. G., Adler, J. A., Ballantyne, J. C., Davies, P., Donovan, M. I., Fishbain, D. A., Foley, K. M., Fudin, J., et al. (2009) · The Journal of Pain · doi:10.1016/j.jpain.2008.10.008 · Cited by 2,192
The epidemiology and impact of pain in osteoarthritis
Neogi, T. (2013) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2013.03.018 · Cited by 1,730
The Rising Prevalence of Chronic Low Back Pain
Freburger, J. K., Holmes, G. M., Agans, R. P., Jackman, A. M., Darter, J. D., Wallace, A. S., Castel, L. D., Kalsbeek, W. D., & Carey, T. S. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.543 · Cited by 1,507 · cited 1×
“Indeed, an estimated 10% of individuals report chronic, impairing low back pain, of whom 84% seek health care.(51) When managing”
BackgroundReid, K. J., Harker, J., Bala, M. M., Truyers, C., Kellen, E., Bekkering, G. E., & Kleijnen, J. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.545813 · Cited by 476 · cited 1×
“and has an estimated prevalence of approximately 20%.(1,2) In cancer patients, moderate-to-severe chronic”
BackgroundLow back pain and sciatica in over 16s: assessment and management NICE guideline [NG59].
de Campos, T. F. (2017) · Journal of physiotherapy · doi:10.1016/j.jphys.2017.02.012 · Cited by 338
Managing chronic pain in the non-specialist setting: a new SIGN guideline
Smith, B. H., Hardman, J. D., Stein, A., & Colvin, L. (2014) · British Journal of General Practice · doi:10.3399/bjgp14x680737 · Cited by 16
Cited by
Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review
Seppi, K., Ray Chaudhuri, K., Coelho, M., Fox, S. H., Katzenschlager, R., Perez Lloret, S., Weintraub, D., Sampaio, C., & and the collaborators of the Parkinson's Disease Update on Non‐Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence‐Based Medicine Committee (2019) · Movement Disorders · doi:10.1002/mds.27602 · Cited by 1,007
Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines
Fallon, M., Giusti, R., Aielli, F., Hoskin, P., Rolke, R., Sharma, M., & Ripamonti, C. I. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy152 · Cited by 954
A brief history of the opioid epidemic and strategies for pain medicine
Jones, M. R., Viswanath, O., Peck, J., Kaye, A. D., Gill, J. S., & Simopoulos, T. T. (2018) · Pain and Therapy · doi:10.1007/s40122-018-0097-6 · Cited by 405
Larkin, P. J., Cherny, N. I., La Carpia, D., Guglielmo, M., Ostgathe, C., Scotté, F., & Ripamonti, C. I. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy148 · Cited by 273
Clinical Pharmacokinetics and Pharmacodynamics of Naloxone
Saari, T. I., Strang, J., & Dale, O. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01355-6 · Cited by 77
Metadata
- Authors
- Morlion, B. J., Mueller‐Lissner, S. A., Vellucci, R., Leppert, W., Coffin, B. C., Dickerson, S. L., & O'Brien, T.
- Venue
- Pain Practice
- Publisher
- Wiley
- Published
- 2017-11-28
- Volume
- 18
- Issue
- 5
- Pages
- 647-665
- ISSN
- 1530-7085 (ISSN-L)
- 1533-2500
- OpenAlex
- W2759407993
- Cited by
- 41
- References
- 10
- FWCI
- 6.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.